कृपया अन्य खोज का प्रयास करें
United BioPharma, Inc. develops, manufactures, and markets monoclonal antibody (mAb) products and biosimilar antibodies in Taiwan. Its molecules product pipeline includes UB-421 for the treatment of AIDS; UB-621, an anti-herpes simplex virus mAb; UB-221, which is in phase I trial for the treatment of Chronic urticaria; UB-721 that is in process development for the treatment of autoimmune diseases; UB-923 that is in manufacturing process development for the treatment of non-hodgkin’s lymphoma, rheumatoid arthritis, etc.; UB-925, which is in process development stage for the treatment of gastric, colorectal, and non-small cell lung cancer; and UB-926 that is in process development stage for the treatment of breast cancer. The company’s biosimilars under development also comprise UB-921, which is in Phase I clinical trial for the treatment of breast cancer; and UB-922, which is in process development for the treatment of colorectal, brain, renal cell, and non-small cell cancers. It has a collaboration agreement with Shanghai Public Health Clinical Centre and Cheng Kung University's Department of Microbiology and Immunology for long-acting herpes treatment UB-621. United BioPharma, Inc. was founded in 2013 and is based in Taipei, Taiwan.
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है